Abbott ABT Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| Diagnostic Products | $2.18B-11.3% | $2.46B+9.1% | $2.25B+3.7% | $2.17B+5.8% | $2.05B-18.5% | |
| Established Pharmaceuticals | $1.43B+3.2% | $1.38B-8.5% | $1.51B+9.3% | $1.38B+9.8% | $1.26B-0.6% | |
| Medical Devices | $5.54B-2.4% | $5.68B+4.2% | $5.45B+1.5% | $5.37B+9.7% | $4.9B-3.1% | |
| Nutritional Products | $2.02B+4.0% | $1.94B-9.9% | $2.15B-2.7% | $2.21B+3.1% | $2.15B+0.8% | |
| Total Assets by Business | ||||||
| Diagnostic Products | $9.63B+16.4% | $8.27B+0.9% | $8.2B+0.3% | $8.18B+4.3% | $7.84B+2.1% | |
| Established Pharmaceuticals | $3.67B+3.5% | $3.54B-5.1% | $3.73B-0.1% | $3.73B+8.2% | $3.45B+11.7% | |
| Medical Devices | $10.98B+2.8% | $10.69B+1.1% | $10.58B+0.2% | $10.56B+5.2% | $10.03B+5.9% | |
| Nutritional Products | $4.9B+2.3% | $4.79B-2.0% | $4.89B-0.4% | $4.91B+5.9% | $4.64B+5.2% | |
| Operating Earnings by Business | ||||||
| Diagnostic Products | $335M-45.0% | $609M+52.3% | $400M+7.5% | $372M+3.6% | $359M-41.2% | |
| Established Pharmaceuticals | $365M+43.1% | $255M-34.8% | $391M+13.0% | $346M+16.1% | $298M+10.0% | |
| Medical Devices | $1.89B-4.3% | $1.98B+8.1% | $1.83B+1.8% | $1.8B+11.6% | $1.61B-9.2% | |
| Nutritional Products | $311M-19.4% | $386M+7.2% | $360M-13.9% | $418M+6.1% | $394M-11.1% | |
| Selling, general, and administrative by Business | ||||||
| Diagnostic Products | $448M+17.0% | $383M-7.3% | $413M-2.4% | $423M+7.9% | $392M-4.6% | |
| Established Pharmaceuticals | $376M-0.3% | $377M+3.6% | $364M+0.3% | $363M+3.4% | $351M+7.3% | |
| Medical Devices | $1.39B+0.1% | $1.39B-0.2% | $1.39B+0.4% | $1.39B+7.6% | $1.29B+2.2% | |
| Nutritional Products | $563M+29.4% | $435M-15.5% | $515M-12.0% | $585M+1.6% | $576M+17.6% | |
| Cost of products sold, excluding amortization of intangible assets by Business | ||||||
| Diagnostic Products | $1.24B+114% | -$8.65B-771% | $1.29B+5.4% | $1.22B+6.3% | $1.15B+113% | |
| Established Pharmaceuticals | $644M+114% | -$4.53B-734% | $714M+13.2% | $631M+10.9% | $569M+113% | |
| Medical Devices | $1.81B+115% | -$12.1B-785% | $1.77B+0.5% | $1.76B+10.0% | $1.6B+114% | |
| Nutritional Products | $1.09B+113% | -$8.07B-760% | $1.22B+5.9% | $1.16B+2.8% | $1.12B+114% | |
| R&D by Business | ||||||
| Diagnostic Products | $155M+5.4% | $147M-2.0% | $150M-2.6% | $154M+2.0% | $151M-13.2% | |
| Established Pharmaceuticals | $41M-16.3% | $49M+16.7% | $42M-2.3% | $43M+2.4% | $42M-6.7% | |
| Medical Devices | $444M-3.5% | $460M-0.4% | $462M+7.4% | $430M+7.2% | $401M+2.6% | |
| Nutritional Products | $54M+3.8% | $52M-5.5% | $55M+1.9% | $54M+3.8% | $52M+2.0% | |
| Additions to Property and Equipment by Business | ||||||
| Diagnostic Products | $128M-56.2% | $292M+73.8% | $168M+1.2% | $166M+23.0% | $135M-52.3% | |
| Established Pharmaceuticals | $20M-66.1% | $59M+55.3% | $38M-2.6% | $39M+18.2% | $33M-49.2% | |
| Medical Devices | $147M-32.3% | $217M+55.0% | $140M-3.4% | $145M-7.1% | $156M-16.1% | |
| Nutritional Products | $40M-43.7% | $71M0.0% | $71M-12.3% | $81M+2.5% | $79M-21.0% | |
| Remaining performance obligations by Business | ||||||
| Diagnostic Products | $6.2B+1.6% | $6.1B+1.7% | $6B+1.7% | $5.9B+3.5% | $5.7B+3.6% | |
| Medical Devices | $429M-3.4% | $444M+1.8% | $436M+2.1% | $427M+0.9% | $423M-3.9% | |
| Depreciation by Business | ||||||
| Diagnostic Products | $144M+5.9% | $136M0.0% | $136M+0.7% | $135M+7.1% | $126M-6.0% | |
| Established Pharmaceuticals | $30M+20.0% | $25M-10.7% | $28M+12.0% | $25M+8.7% | $23M-8.0% | |
| Medical Devices | $100M+1.0% | $99M+2.1% | $97M+3.2% | $94M+6.8% | $88M+7.3% | |
| Nutritional Products | $50M+19.0% | $42M-10.6% | $47M+6.8% | $44M+4.8% | $42M-2.3% | |
| Goodwill, non-deductible by Business | ||||||
| Diagnostic Products | $14.9B+314% | $3.6B0.0% | $3.6B0.0% | $3.6B+2.9% | $3.5B0.0% | |
| Established Pharmaceuticals | $2.7B0.0% | $2.7B0.0% | $2.7B0.0% | $2.7B+3.8% | $2.6B0.0% | |
| Medical Devices | $17.3B-0.6% | $17.4B0.0% | $17.4B+0.6% | $17.3B+2.4% | $16.9B+0.6% | |
| Nutritional Products | $300M+5.3% | $285M0.0% | $285M0.0% | $285M0.0% | $285M0.0% | |
| Net Sales by Geography | ||||||
| International | $6.89B-2.6% | $7.08B+0.1% | $7.07B+3.0% | $6.87B+10.9% | $6.19B-6.7% | |
| United States | $4.27B-2.5% | $4.38B+2.0% | $4.3B+0.5% | $4.28B+2.6% | $4.17B-4.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Abbott break its business down?
- Abbott (ABT) reports net sales by business across 4 parts — Diagnostic Products, Established Pharmaceuticals, Medical Devices and Nutritional Products. Each is extracted from the segment footnotes and tracked over time.
- Where does Abbott's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Abbott's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
